Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C35H49N11O9S2 |
Molecular Weight | 831.962 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCN1C(=O)[C@H](CC3=CNC4=CC=CC=C34)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(N)=N)NC(=O)CCSSC[C@H](NC2=O)C(N)=O
InChI
InChIKey=CZKPOZZJODAYPZ-LROMGURASA-N
InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1
Molecular Formula | C35H49N11O9S2 |
Molecular Weight | 831.962 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/020718s034lbl.pdfCurator's Comment: Description was created using several sources including:
http://www.ncbi.nlm.nih.gov/pubmed/10577440; http://www.drugbank.ca/drugs/DB00063
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/020718s034lbl.pdf
Curator's Comment: Description was created using several sources including:
http://www.ncbi.nlm.nih.gov/pubmed/10577440; http://www.drugbank.ca/drugs/DB00063
Eptifibatide is a platelet aggregation inhibitor - an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. It is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake. It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner. It is used for treatment of myocardial infarction and acute coronary syndrome.
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10577440
Curator's Comment: Integrilin (Eptifibatide) was invented by Robert M. Scarborough and David Phillips, at COR Therapeutics, Inc.The company was acquired by Millennium Pharmaceuticals, Inc. , MA in 2001.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093869 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10577440 |
8.7 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/020718s034lbl.pdf |
Primary | INTEGRILIN Approved UseEptifibatide Launch Date9.2871361E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. | 2000 Sep 21 |
|
Binding of a fibrinogen mimetic stabilizes integrin alphaIIbbeta3's open conformation. | 2001 Aug |
|
Comparison of eptifibatide and abciximab with decision analysis. | 2001 Aug 1 |
|
There is synergism between high-intensity, low-frequency ultrasound and streptokinase but not with eptifibatide, heparin, and aspirin. Differential effects on fresh and aged blood clots. An in vitro study. | 2001 Aug 15 |
|
[Economic evaluation of eptifibatide]. | 2001 Feb |
|
[Inhibitors of platelet glycoprotein IIb-IIIa in cardiology]. | 2001 Jan-Feb |
|
Glycoprotein IIb/IIIa inhibitors: more different than alike? | 2001 Jul |
|
Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation. | 2001 Jun 15 |
|
Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. | 2001 Mar |
|
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. | 2001 Mar 1 |
|
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention. | 2001 May |
|
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. | 2001 May |
|
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. | 2001 May 29 |
|
Drug-company sponsorship and the Declaration of Helsinki. | 2001 May 5 |
|
Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. | 2001 Nov |
|
Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. | 2001 Nov 1 |
|
Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. | 2001 Oct |
|
Modulation of platelet aggregation in baboons: implications for mixed chimerism in xenotransplantation. I. The roles of individual components of a transplantation conditioning regimen and of pig peripheral blood progenitor cells. | 2001 Oct 15 |
|
Severe thrombocytopenia possibly related to readministration of eptifibatide. | 2001 Sep |
|
Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. | 2001 Sep 1 |
|
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? | 2002 Feb 5 |
|
Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. | 2002 Jan |
|
Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. | 2002 Jan |
|
Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact. | 2002 Jan 15 |
|
A synthetic polymer matrix for the delayed or pulsatile release of water-soluble peptides. | 2002 Jan 17 |
|
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. | 2002 Jan 22 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/020718s034lbl.pdf
Curator's Comment: The recommended adult dosage of eptifibatide in patients with acute coronary syndrome and normal renal function is an intravenous bolus of 180 mcg/kg as soon as possible following diagnosis, followed by a continuous infusion of 2.0 mcg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours.
180 ug/kg
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: Overall, eptifibatide rapidly inhibits in vitro platelet aggregation in blood samples, with an IC50 in the 100 to 600 nmol/L range, depending on the extracellular concentration of ionized calcium; at a low concentration of 40 to 50 μmol/L, the IC50 is approximately 100 nmol/L, whereas at physiologic concentration of approximately 1.1 μmol/L, IC50 is closer to 500 nmol/L
100 - 600 nmol/L
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:52:31 UTC 2023
by
admin
on
Sat Dec 16 15:52:31 UTC 2023
|
Record UNII |
NA8320J834
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
||
|
NDF-RT |
N0000008832
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
||
|
WHO-ATC |
B01AC16
Created by
admin on Sat Dec 16 15:52:31 UTC 2023 , Edited by admin on Sat Dec 16 15:52:31 UTC 2023
|
||
|
NDF-RT |
N0000175578
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
INTEGRILIN (AUTHORIZED: ANGINA, UNSTABLE)
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
||
|
WHO-VATC |
QB01AC16
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
||
|
FDA ORPHAN DRUG |
364012
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
INTEGRILIN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
||
|
NDF-RT |
N0000008832
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB12498MIG
Created by
admin on Sat Dec 16 15:52:31 UTC 2023 , Edited by admin on Sat Dec 16 15:52:31 UTC 2023
|
PRIMARY | |||
|
100000089288
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
148031-34-9
Created by
admin on Sat Dec 16 15:52:31 UTC 2023 , Edited by admin on Sat Dec 16 15:52:31 UTC 2023
|
SUPERSEDED | |||
|
291902
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
C086648
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
DTXSID7046673
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
m4968
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB00063
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
75635
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | RxNorm | ||
|
Eptifibatide
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
1238501
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
CHEMBL1174
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
6585
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
188627-80-7
Created by
admin on Sat Dec 16 15:52:31 UTC 2023 , Edited by admin on Sat Dec 16 15:52:31 UTC 2023
|
PRIMARY | |||
|
8313
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
1040
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
EPTIFIBATIDE
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
448812
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
II-61
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
C47516
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
NA8320J834
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
7717
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY | |||
|
NA8320J834
Created by
admin on Sat Dec 16 15:52:32 UTC 2023 , Edited by admin on Sat Dec 16 15:52:32 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|